

Omnia Challenges PainTEQ Intellectual Property

Omnia Medical announced PTAB will allow Omnia Medical's petition for inter parties review of PainTEQ patent.



MORGANTOWN, WEST VIRGINIA,
UNITED STATES, January 9, 2024
/EINPresswire.com/ -- [Omnia Medical](#), a
medical device company committed to

providing the industry with innovative solutions utilizing proven techniques, announced that the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office on Thursday September 20th granted institution in IPR2023-00625. In other words, the PTAB decided it would allow Omnia Medical's Petition for inter parties review of PainTEQ patent "11,020,129 B2 Drill-less

Method of Fusing a Sacroiliac Joint" to proceed, finding that there is reasonable likelihood that challenged claims 1, 2, 9, and 10 in the PaintEQ patent, U.S. 11,020,129, (the '129 patent) are invalid in view of the grounds presented in Omnia Medical's petition.

“

We are pleased with the PTAB's decision and look forward to the final resolution of this petition.”

*Troy Schifano, CEO of Omnia
Medical*

“We are pleased with the PTAB's decision and look forward to the final resolution of this petition. As is evidenced by our existing and expanding patent portfolio and resulting

consolidated Federal Courts cases with PainTEQ, we take Intellectual Property rights very seriously.” said Troy Schifano, CEO of Omnia Medical.

For those interested in accessing more information about the above referenced ongoing IPR, including status and prior art cited against the patent, please visit <https://ptacts.uspto.gov/ptacts/ui/home> and reference IPR number IPR2023-00625.

For those interested in accessing more information about the above referenced consolidated Federal Court Cases, including court details and case numbers, please visit <https://www.flmd.uscourts.gov/pacer> and reference US District Court – Middle District of Florida case number 8:20-cv-02805-VMC-AAS.

Christopher Henneforth

Omnia Medical
chenneforth@omniamedical.com

This press release can be viewed online at: <https://www.einpresswire.com/article/680121353>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.